Duodenal Ulcer is an indication for drug development with over 10 pipeline drugs currently active. According to GlobalData, preregistered drugs for Duodenal Ulcer have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Duodenal Ulcer compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Duodenal Ulcer overview

Duodenal ulcers, a subset of peptic ulcer disease, result from a disruption in the mucosal surface of the duodenum, the initial segment of the small intestine. The primary culprit behind this condition is infection with Helicobacter pylori (H. pylori) bacteria. H. pylori induces inflammation in the duodenal lining, leading to ulcer formation. Certain medications, especially anti-inflammatory drugs like ibuprofen and aspirin, can also contribute to duodenal ulcers. Treatment commonly involves “triple therapy”, utilizing two antibiotics and an acid-reducing medicine. The antibiotics target bacteria, while the acid-reducing medication aids in healing the ulcer and preventing recurrence.

For a complete picture of PTSR and LoA scores for drugs in Duodenal Ulcer, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.